DSF, its monomer DDTC, and their derivatives are widely recognized as inhibitors of the NF-kB pathway [53, 54], and it is well-established that NF-kB inhibition sensitizes tumor cells to commonly used chemotherapeutic agents [55]. Here, NFKB1 is linked to neoplasm.